Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-446.49%
operating margin TTM
-395.9%
revenue TTM
30.19 Million
revenue per share TTM
0.55$
valuation ratios | |
|---|---|
| pe ratio | -0.22 |
| peg ratio | 0.30 |
| price to book ratio | -0.47 |
| price to sales ratio | 0.97 |
| enterprise value multiple | -0.13 |
| price fair value | -0.47 |
profitability ratios | |
|---|---|
| gross profit margin | 88.92% |
| operating profit margin | -395.9% |
| pretax profit margin | -446.49% |
| net profit margin | -446.49% |
| return on assets | -220.81% |
| return on equity | 494.02% |
| return on capital employed | -427.8% |
liquidity ratio | |
|---|---|
| current ratio | 1.66 |
| quick ratio | 1.47 |
| cash ratio | 1.22 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 702.90 |
| operating cycle | 747.44 |
| days of payables outstanding | 387.92 |
| cash conversion cycle | 359.52 |
| receivables turnover | 8.19 |
| payables turnover | 0.94 |
| inventory turnover | 0.52 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.88 |
| debt equity ratio | -0.84 |
| long term debt to capitalization | -1.67 |
| total debt to capitalization | -5.21 |
| interest coverage | -7.28 |
| cash flow to debt ratio | -2.05 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.03 |
| cash per share | 0.74 |
| operating cash flow per share | -2.01 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -2.05 |
| short term coverage ratios | -8.52 |
| capital expenditure coverage ratio | -96.75 |
Frequently Asked Questions
When was the last time Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) reported earnings?
Marinus Pharmaceuticals, Inc. (MRNS) published its most recent earnings results on 12-11-2024.
What is Marinus Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)'s trailing twelve months ROE is 494.02%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Marinus Pharmaceuticals, Inc. (MRNS) currently has a ROA of -220.81%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did MRNS's net profit margin stand at?
MRNS reported a profit margin of -446.49% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is MRNS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.66 in the most recent quarter. The quick ratio stood at 1.47, with a Debt/Eq ratio of -0.84.